Dr Yajing Zhang

Dr. Yajing Zhang is currently the Director of Hematology and CAR T Cell Therapy Center at Beijing Gobroad Hospital, Beijing, China.

Dr. Yajing Zhang’s qualifications are MD, PhD, Postdoctoral Fellow, and Master’s Supervisor.

Specialty and expertise:

Specializes in immunotherapy, targeted therapy, combination therapy exploration, and personalized treatment for various relapsed and refractory malignant tumors.

Academic Status:

Member of the Committee on Cellular Therapy and Biotherapy of the Chinese Research Hospital Association;
Core Expert on Hematologic Oncology Rehabilitation for the China Cancer Foundation;
Executive Member of the Committee for the Promotion of Basic and Clinical Research of the China Medical Education Association;
Member of the Editorial Board of the Special Issue on Cellular and Immunotherapy in the Chinese Edition of JCO-Blood;
Member of the Committee on Cellular Immunotherapy of the China Health Promotion and Education Association;
Reviewer for the National Natural Science Foundation of China;

Research Achievements:

Principal Investigator for six projects, including those funded by the National Natural Science Foundation of China and the Beijing Science and Technology Commission;Published multiple SCI papers as the first author in journals such as Blood and Leukemia, with a cumulative impact factor of over 100 points;
Received the First Prize for Outstanding Scientific and Technological Innovation Papers in South China and the Second Prize for Scientific and Technological Progress at the PLA General Hospital;
Authored and published the first domestic “Guidelines for Managing Adverse Reactions of CAR-T Therapy for Lymphoma”

Public Engagement:

Won the National Second Prize in the TED Case Competition for Young and Middle-Aged Experts in the Field of Lymphoma in China;

Listed in the Top 10 of China’s Good Doctors in 2020

Main research direction:

Application research of tumor immunotherapy in lymphomas. Published multiple SCI papers as the first author in journals such as Blood and Leukemia, accumulating an impact factor of over 100;

Member of the Biotherapy Committee of the Chinese Research Hospital Association.

• Lymphoma
• Leukemia
• Hematological malignancies
• Multiple myeloma

• CAR T-Cell therapy
• Bone marrow transplant
• Chemotherapy
• Immunotherapy